Ann: Positive feedback received on Paediatric Investigation Plan, page-212

@samfiodiving.

Given we know that ANP knows that it has an EMA approval and that there are strong connections between Sarepta’s past leadership team and ANP’s. What if the time to announcement has required coordination of not just Sarepta but perhaps another party with a European presence and an equal desire to show efficacy? Given what has been suggested around value, what if there was a need for an additional partner like Roche, already on the hook with Sarepta, to gain access to the benefits of ATL1102 and be included in the deal? Simply speculation on my part but its pretty clear to me that if ANP simply wanted a CR for the European trial they would have already announced it.